stoxline Quote Chart Rank Option Currency Glossary
  
Indaptus Therapeutics, Inc. (INDP)
2.24  -0.25 (-10.04%)    03-28 16:00
Open: 2.39
High: 2.42
Volume: 55,301
  
Pre. Close: 2.49
Low: 2.03
Market Cap: 19(M)
Technical analysis
2024-03-28 4:52:13 PM
Short term     
Mid term     
Targets 6-month :  2.85 1-year :  3.42
Resists First :  2.44 Second :  2.92
Pivot price 2.19
Supports First :  1.66 Second :  1.38
MAs MA(5) :  2.46 MA(20) :  2.16
MA(100) :  1.97 MA(250) :  2.16
MACD MACD :  0.1 Signal :  0.1
%K %D K(14,3) :  61.8 D(3) :  74.2
RSI RSI(14): 52.8
52-week High :  4.07 Low :  1.55
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ INDP ] has closed below upper band by 45.5%. Bollinger Bands are 123.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 2.42 - 2.44 2.44 - 2.45
Low: 2 - 2.02 2.02 - 2.03
Close: 2.22 - 2.24 2.24 - 2.26
Company Description

Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York.

Headline News

Thu, 28 Mar 2024
Should You Buy Indaptus Therapeutics Inc (INDP) Stock After it Has Gained 0.44% in a Week? - InvestorsObserver

Wed, 27 Mar 2024
Is Indaptus Therapeutics (NASDAQ:INDP) In A Good Position To Invest In Growth? - Yahoo Finance

Wed, 27 Mar 2024
Is Indaptus Therapeutics (NASDAQ:INDP) In A Good Position To Invest In Growth? - Simply Wall St

Mon, 18 Mar 2024
Indaptus Therapeutics to Participate in Tribe Public Webinar On Wednesday, March 20, 2024 - BioSpace

Thu, 14 Mar 2024
Indaptus Therapeutics Inc reports results for the quarter ended in December - Earnings Summary - TradingView

Wed, 06 Mar 2024
Should You Buy Indaptus Therapeutics Inc (INDP) Stock After it Has Fallen 5.56% in a Week? - InvestorsObserver

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 9 (M)
Shares Float 6 (M)
Held by Insiders 30.8 (%)
Held by Institutions 7 (%)
Shares Short 34 (K)
Shares Short P.Month 15 (K)
Stock Financials
EPS -1.84
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.44
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -47.7 %
Return on Equity (ttm) -84.1 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -1.92
Qtrly Earnings Growth 0 %
Operating Cash Flow -13 (M)
Levered Free Cash Flow -8 (M)
Stock Valuations
PE Ratio -1.23
PEG Ratio 0
Price to Book value 1.55
Price to Sales 0
Price to Cash Flow -1.43
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android